S troke is a serious complication of diabetes but the risk factors for stroke in these patients are not fully defined. The aim of this retrospective study was to investigate the risk factors for stroke in patients with type 2 diabetes mellitus (T2DM). The group comprised 208 patients with T2DM, and the mean duration of followup was seven years (range 4-11 years). The incidence of stroke was investigated according to lymphocyte proliferation in response to insulin.
Introduction
The number of people with diabetes worldwide is projected to rise from 171 million in the year 2000 to 366 million in 2030. 1 Accordingly, the number of patients with complications of diabetes will increase as well; sometimes these complications represent significant problems. Stroke is one lifethreatening complication. It is well known that diabetes (DM) is a strong risk factor for stroke, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] though the mechanisms are not fully understood. Taking into account the high costs of treatment and rehabilitation of stroke patients, it would be helpful to know which diabetic patients are at risk of stroke.
Patients with type 2 diabetes mellitus (T2DM) are a very heterogeneous group, with different mechanisms of hyperglycaemia. We have previously shown differences in lymphocyte proliferative activity in response to insulin in diabetes, which seem to be related to the type of diabetes and its associated complications. 12 Here we investigate the incidence of stroke according to cell-mediated immunity (CMI) in T2DM. The aim of our investigation was to identify risk factors for stroke in diabetes.
Subjects and methods Subjects
A univariate analysis was made of the risk factors for stroke in a retrospective cohort of patients with T2DM. Patients with a clinical diagnosis of acute stroke who were admitted to the Central District Hospital during the period 1st January 2003 to 31st December 2003 were enrolled into the study. The mean duration of follow-up was seven years (range 4-11 years). A total of 208 patients were included, and their clinical characteristics are presented in table 1. Newly diagnosed patients with diabetes received oral hypoglycaemic therapy with metformin or a sulphonylurea; in addition, 4.8% of patients were given a statin and 38% were given aspirin 125 mg/day. In all, 93 patients (44.7%) needed additional insulin therapy (8-48 units/day) and 34 patients received insulin during the first three years.
The patients were selected by a simple random sampling method. Duration of disease, smoking, fasting blood glucose, total cholesterol and lipoprotein concentrations and arterial hypertension were determined from the casenotes. These were considered to be possible risk factors, as were functional activity of specific cells with histamine receptors (CHR), prostaglandin-synthesising cells (PGSC) and islet cell antibodies (ICA). All patients in this study were admitted to our hospital with stroke between October 1993 and October 2004. The World Health Organization definition of acute stroke was used: 'rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular origin'. Stroke was classified as ischaemic or haemorrhagic.
A critical harbinger of impending stroke is transient ischaemic attacks (TIA). These are defined as neurological deficit due to focal cerebral or retinal ischaemia which lasts less than 24 hours and resolves. Patients with TIA were also included in this study.
Methods
Cell-mediated immunity to insulin (Ins) was investigated. peripheral blood mononuclear cells (PBMC) were separated from whole blood using a Ficoll-Hypaque gradient and were used for the lymphocyte proliferation assay. The viability of isolated cells ranged from 95% to 98%. Cells were washed twice in RPMI 1640 and resuspended at a concentration of 2 x 10 6 /ml of complete RPMI 1640 supplemented with penicillin-streptomycin (100 U/ml), 5% fetal calf serum. Cells were placed in duplicate into tubes and were incubated with liver-specific lipoprotein (0.025 mg/well), insulin (0.08 unit/well, Humulin regular, Lilly SA, France), with or without indometacin (0.0025 mg/well) and cimetidine (0.02 mg/well) for four days. Pilot experiments demonstrated no proliferative activity of cells from healthy persons exposed to antigens at these doses.
Cimetidine (Cim) was added to the cell culture for inhibition of cells with histamine receptors; indometacin (Ind) was added to the cell culture for inhibition of prostaglandin-synthesising cells. 13 Direct CMI was estimated as lymphocyte proliferation to Ins alone. Addition of Ind and Cim to Ins in cell culture showed indirect CMI to insulin that was suppressed by PGSC or CHR, respectively.
We measured spontaneous and antigen-induced proliferative activity by counting lymphoblastic cells in culture. A positive response was defined as one in which the percentage of transformed cells was greater than 50%. Preliminary results show a positive correlation (r+0.501 to +0.768 dependent upon antigen) between H 3 -thymidine incorporation and number of blast cells in culture. As a negative control we used unstimulated cell culture (in all patients) and cell culture with liver-specific lipoprotein (in 96 patients).
Islet cell antibodies (ICA) were detected in the serum of 50 randomly-selected patients with diabetes by an indirect immunofluorescence test using Islet Cell Antibody System (IMMCO diagnostics, Inc., US).
Statistical analysis
The mortality rate and the incidence of stroke in the general population (n=52,100) and in the diabetic patients (n=550) in Sasovo District, Ryazan Region, Russia, were determined.
The results were analysed statistically using chi-squared and Student's t-test. Significance was ascribed to p<0.05 and values are given as mean +/-standard deviation. The sensitivity and specificity of the diagnostic methods and the relative risk were calculated. 14 
Results

Statistical data
Between January 1st and December 31st 2003, stroke was identified in 188 from 52,100 (3.5/1,000) people from the general population; the mortality rate was 1.4%. Among diabetic patients stroke was identified in 16/550 (29.1/1,000), giving an incidence rate eight times higher than that in the same age group (over 45 years) of the general population. In half the diabetic patients stroke was fatal, which is significantly higher than the rate found in the general population (p<0.001).
Cohort study
Between October 1993 and October 2004, stroke was identified in 37 patients with diabetes. Of these, seven patients had transient ischaemic attacks, 24 had an ischaemic stroke and six haemorrhagic stroke. Male and female subjects have been analysed separately: in this cohort men had a higher incidence of stroke than women but the difference was not significant (16/74 vs. 21/134, p>0.05).
ICA were identified in 24 of 50 patients. ICA were not associated with stroke or treatment, but ICA-positive patients were given insulin earlier and in high doses.
CMI to liver-specific lipoprotein was present in 1/96 patients. Direct CMI to this antigen was absent in all investigated patients (96, including 18 patients with stroke). Indirect CMI after inhibition of PGSC was found in one patient with diabetes but without stroke. Indirect CMI after CHR blocking by Cim was absent in all investigated patients (45, including 12 patients with stroke).
By contrast, CMI to Ins was observed in 188/208 diabetic patients: 30 of them had direct CMI and 158/188 had indirect CMI (59 after inhibition of CMR, 99 after inhibition of PGSC).
Patients with T2DM were divided into four subgroups according to the immunological findings. The first group consisted of 30 patients with direct CMI to Ins. ICA were revealed in the serum of 10 patients who were investigated (10/10). These patients probably had latent autoimmune diabetes of adults (LADA).
The second group consisted of 59 patients with indirect CMI to Ins, revealed after inhibition of CMI by Cim. ICA were revealed in the serum of 14 patients who were investigated (14/14). All these patients had a routine course of T2DM.
The third group consisted of 99 patients with indirect CMI to Ins, revealed after inhibition of PGSC by Ind. None of the investigated patients had ICA (0/19). All these patients also had a routine course of T2DM.
The fourth group consisted of 20 patients without CMI to Ins (either direct or indirect). None of the investigated patients had ICA (0/7). These patients had pancreatogenic diabetes.
The incidence of stroke according to these CMI subgroups is presented in table 2. Stroke was more common in the second and third groups, those with indirect immunity to Ins. Patients from the second group, with high activity of CHR, were younger. TIA occurred only in the third group, those with high activity of PGSC. In marked contrast, the incidence of stroke was low in the first group (direct CMI to Ins) and stroke was absent from the fourth group (no CMI to Ins). The relative risk of stroke was significantly higher in T2DM patients with indirect CMI to insulin than in the other groups (5.54 vs. 1.40). The incidence of stroke was not associated with duration of disease, smoking, fasting blood glucose, total cholesterol or lipoprotein concentrations, or arterial hypertension (p>0.05).
Discussion
The results of our investigation of the mortality rate and the incidence of stroke are in concordance with the results of previous studies, and they indicate that T2DM is a strong risk factor for stroke. In patients with disturbances of carbohydrate metabolism the course of stroke is worse, the period of rehabilitation is longer and the mortality rate is higher. 9, [15] [16] [17] [18] [19] The severity of stroke in diabetes is explained by a cluster of factors termed 'metabolic syndrome', that is characterised by insulin resistance, hyperinsulinaemia, hyperglycaemia, arterial hypertension, obesity and dyslipidaemia. All these factors promote vascular injury: not only do they increase the risk of stroke but they also account for the severity of disease. It has been shown 20 that the greater the number of components of the metabolic syndrome, the more often complications (including stroke) develop. Although these studies clearly show that diabetes is a risk factor for stroke, they fail to address the risk factors for stroke in subjects with diabetes.
It would be invaluable to discover the risk factors because this could help in prevention of the late complications of diabetes and could reduce the mortality rate in stroke. We found, on multivariate analysis of risk factors, including smoking, dyslipidaemia, arterial hypertension, hyperinsulinaemia and hyperglycaemia, that insulin resistance alone or in asso-ciation with hyperinsulinaemia or dyslipidaemia was a risk factor for stroke in healthy adults and in T2DM patients. For some authors this association remains controversial. 11, [21] [22] [23] Our results (a high incidence of stroke in patients with indirect CMI to insulin) lead us to conclude that high functional activities of cells with histamine receptors and prostaglandin-synthesising cells are risk factors for stroke development. This enhanced risk might be caused by their role in the development of insulin resistance (IR), an important aspect of T2DM.
It is possible that the immune system is somehow responsible for the development of IR. It has been reported previously that T2DM is characterised by high activities of specific CHR (Se 60%, Sp 99%) and PGSC (Se 71%, Sp 75%). 12 These cells block insulin receptors on immunocompetent cells because CMI to Ins appears in patients after inactivation of CHR or PGSC. However, CHR and PGSC may inhibit insulin receptors not only on lymphocytes but in other insulin-sensitive tissues, such as liver, adipose tissue and muscle.
The use of H 2 receptor blockers such as ranitidine in the treatment of patients with high activity of CHR and the use of prostaglandin synthetase inhibitors such as indometacin in the treatment of patients with high activity of PGSC has been shown to result in decreased fasting blood glucose. 24 We could not find a study on the effect of ranitidine in T2DM. However, there are many studies in which beneficial or deleterious effects of non-steroidal anti-inflammatory drugs on insulin sensitivity have been shown. [25] [26] [27] [28] [29] [30] The beneficial effects of prostaglandin inhibitors may depend on their influence on PGSC activity and would therefore be absent in healthy persons, who have normal activity of these cells. It has been shown 29 that high-dose aspirin improves glucose metabolism in T2DM by inhibiting IkB kinase (IKKb) activity, and this is of importance in the pathophysiology of insulin resistance. Taking into account these investigations and the results of our study, we propose that high activities of CHR-and PGSCmediated insulin inhibition may be responsible for the development of insulin resistance.
The influence of these two varieties of suppressor cells is not identical. High PGSC activity is typical of ageing: it was found in one third of elderly people in previous studies, and was associated with cerebrovascular disease in that stroke developed only when hyperglycaemia appeared. 12, 24, 31, 32 Indirect CMI to insulin with high PGSC activity is associated with a routine course of T2DM and is usually characterised by later onset of diabetes and correction of glucose abnormalities early in the clinical course through diet, change of lifestyle or oral therapy.
A different clinical course may be observed in patients with high CHR activity. We have shown the association of this type of indirect CMI to insulin with macrovascular complications (myocardial infarction, stroke, diabetic foot problems); 12 it may be explained by participation of other cells in the development of IR. This type of insulin resistance is not found in healthy or elderly people: it is usually found in diabetic patients with high blood glucose levels. However, these patients feel well, often do not know about their high level of glucose and visit their doctor late, usually when severe vascular problems have already developed.
ORIGINAL ARTICLE According to the results of our current study, stroke develops more often in this group of patients. Mild forms of stroke such as TIA are not found in this group; on average, stroke develops 12.3 years earlier than in LADA patients and 7.2 years earlier than in patients with high PGSC activity.
We conclude that high activity of CHR, which inhibits CMI to insulin, is associated with stroke and represents a risk factor for this complication. High activity of PGSC, which inhibits CMI to insulin, is also associated with stroke, but in addition may be found in elderly patients with less severe cerebrovascular insufficiency. In this group the association is not significant but the incidence of stroke is higher than in the first group.
The long-term observation of functional activities of PGSC and CHR in diabetic patients did not reveal changes in lymphocyte proliferation with the course of disease, complications of diabetes or addition of insulin to the treatment regime. This is very important because these factors are not modifiable and may be revealed at the onset of diabetes.
The duration of diabetes is an important factor contributing to the risk of stroke, 18 but often the onset of diabetes is unknown as the disease may be asymptomatic initially, making it difficult to estimate the duration of the disease accurately. Sometimes the first manifestation of diabetes is a stroke. Arterial hypertension, obesity and atherosclerosis probably play a role in the development of stroke in subjects with diabetes and these are all elements of the IR syndrome. In recent years, a role for subclinical inflammation in the pathogenesis of insulin resistance, obesity and T2DM has been highlighted. 33, 34 Histamine and prostaglandins are wellknown mediators of inflammation, and high activities of PGSC and CHR may play a role in the development of insulin resistance and diabetes.
Conclusion
Our results indicate that T2DM is a risk factor for stroke, and that high activity of CHR and PGSC cells accounts for this increased risk. These cells suppress CMI to insulin and may promote the development of insulin resistance.
CMI to insulin, that was revealed after the inhibition of suppressor cell activity by cimetidine (which is specific for CHR), is a strong risk factor for stroke. CMI to insulin that was revealed after the inhibition of suppressor cell activity by indometacin (which is specific for PGSC), is a weaker risk factor for stroke.
